Equities

Hanshang Group Co Ltd

600774:SHH

Hanshang Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)7.50
  • Today's Change0.01 / 0.13%
  • Shares traded12.46m
  • 1 Year change-24.92%
  • Beta1.3069
Data delayed at least 15 minutes, as of Oct 11 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hanshang Group Co Ltd, formerly Wuhan Hanshang Group Co Ltd is a China-based company principally engaged in the retail of commodities. The Company is also engaged in the exhibition business, hotel business, tourism business and property management business. The Company mainly operates its retail business through department stores, shopping malls and specialty stores. The Company mainly operates 21st Century Shopping Mall, Ginza Mall and Wuzhan Shopping Center.

  • Revenue in CNY (TTM)1.31bn
  • Net income in CNY21.51m
  • Incorporated1990
  • Employees2.38k
  • Location
    Hanshang Group Co LtdNo. 134, Hanyang AvenueWUHAN 430050ChinaCHN
  • Phone+86 2 768849191
  • Fax+86 2 784842384
  • Websitehttp://www.whhsg.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanghai Shen Lian Biomedical Corp304.79m-12.92m1.99bn380.00--1.38--6.53-0.0315-0.03150.74223.510.1960.92291.15802,082.80-1.065.39-1.125.8464.3677.45-5.4225.485.16--0.001538.49-8.251.85-48.41-18.4910.47--
Hanshang Group Co Ltd1.31bn21.51m2.21bn2.38k98.971.29--1.680.07570.07574.465.830.37182.658.25552,235.400.37292.000.61923.8955.8557.241.004.890.27741.840.379815.030.18935.14-32.2425.6212.88--
Frontier Biotechnologies Inc122.86m-316.34m2.31bn395.00--1.96--18.84-0.8445-0.84450.3283.160.0571.432.91311,049.00-14.67-14.05-17.86-15.7831.822.35-257.47-450.082.11--0.2763--34.82126.637.79--28.13--
Ginwa Enterprise Group Inc556.00m-36.47m2.42bn553.00--1.52--4.34-0.0977-0.09771.494.250.29844.835.591,005,424.00-1.960.3641-2.250.414175.4573.64-6.561.152.66-0.0780.0698124.25-2.41-5.37-228.19--61.66--
Data as of Oct 11 2024. Currency figures normalised to Hanshang Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

1.58%Per cent of shares held by top holders
HolderShares% Held
Gfund Management Co., Ltd.as of 31 Dec 20231.11m0.49%
Penghua Fund Management Co., Ltd.as of 31 Dec 2023653.73k0.29%
Western Leadbank Fund Management Co., Ltdas of 31 Dec 2023613.30k0.27%
Broad Fund Management Co. Ltd.as of 31 Dec 2023612.80k0.27%
E Fund Management Co., Ltd.as of 31 Dec 2023204.70k0.09%
Bosera Asset Management Co., Ltd.as of 31 Dec 202396.10k0.04%
Bodao Fund Management Co Ltd.as of 31 Dec 202387.00k0.04%
Cinda Fund Management Co. Ltd.as of 31 Dec 202376.00k0.03%
HFT Investment Management Co., Ltd.as of 31 Dec 202375.20k0.03%
Changjiang Securities (Shanghai) Asset Management Co., Ltd.as of 31 Dec 202353.80k0.02%
More ▼
Data from 31 Dec 2023 - 06 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.